Navigation Links
Replicon in Medical News

ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference

... its potential mechanism of antiviral action through the selection of a replicon resistant to the antiviral effects of the compound. Resistant HCV replicon sequences were selected in cell culture and resulted in mutations in the ...

Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology

... as a treatment of chronic hepatitis C. Nitazoxanide is a potent inhibitor of hepatitis C virus (HCV) replication in HCV genotype 1-derived replicon cell lines, and in vitro studies have shown that it does not induce mutations in the virus that confer resistance. Phase II clinical trials are ...

Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment

... parameters, ECGs, or vital signs. Steady-state plasma trough levels of TMC435 25 mg and 75 mg represented ~10 and >30-fold excess above the HCV replicon EC50 value, respectively. Mean reductions of HCV RNA from baseline to day seven with TMC435 alone and in triple therapy were 2.63 and 3.47 log10 ...

Morphine Withdrawal Complicates Hepatitis C Infection in Drug Abusers

... events that occur in liver cells. Although the replicon does not produce the infectious virus, the HCV replicon system represents the best available system for ... that there was an increase in the number of HCV replicon in both the withdrawal scenario. Furthermore, ...

Link Between Hepatitis C And Liver Cancer Unraveled By Scientists

... cancer. Reduced quantities of the protein product of the retinoblastoma gene have been found in cells that harbor the Hepatitis C ‘replicon’. A replicon is nothing but a part of the genetic material of the hepatitis C virus that has the intrinsic property of self-replication and protein production. ...
Replicon in Medical Technology

Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008

... genotypes, predominately genotype 4. replicon studies and an early clinical experience ... Nitazoxanide or Tizoxanide in HCV-Containing replicon Cell Lines," also demonstrated that treatment of HCV replicon cells with tizoxanide potentiates the ...

Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research

... ANA598 retained full activity against a number of replicon mutations known to confer resistance to ... of the protein-binding adjusted genotype 1a replicon EC95, suggesting the potential for twice-daily or ... inhibitor, cellular activity in the hepatitis C replicon assay, oral bioavailability and early indicators ...

XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis

... Potency of these compounds was evaluated in a replicon assay, which is known to have good correlation ... clinical testing of inhibitors of HCV. In the replicon assay, the compounds had single-digit nM ... to be significantly more potent than A831 in the replicon assay. A second poster presentation entitled ...

Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)

... activity of the drug and limiting systemic side effects. In an HCV replicon model, IDX184 exhibited 10 times greater potency than the first-generation ... IDX184 demonstrated additive antiviral activity in the HCV replicon in combination with HCV protease inhibitors and interferon and ...

Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection

... including intrinsic potency as an NS5B inhibitor, cellular activity in the replicon assay, oral bioavailability and early indicators of safety and ... concentrations of ANA598 exceeded the EC95 for HCV genotype 1a and 1b replicon inhibition. The EC95 is the concentration required in vitro to suppress ...

AlphaVax Announces Results From Phase 1 Influenza Vaccine Clinical Trial

... trial in 216 volunteers of an influenza vaccine based on its proprietary replicon vector platform. This study was designed to further assess the properties ... vaccine for colon cancer. Additional clinical trials of AlphaVax replicon vaccines for infectious disease, biodefense, and cancer indications are ...

AlphaVax Announces Promising Results in Melanoma Studies

... Annual Meeting in Seattle, Washington. Results from pre-clinical studies conducted at MSKCC demonstrate the ability of AlphaVax's virus-like replicon vector particles (VRP) encoding melanoma-specific tumor antigens to reduce melanoma tumor burden in a state-of-the-art murine melanoma model. ...

Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008

... parameters, ECGs, or vital signs. Steady-state plasma trough levels of TMC435 25 mg and 75 mg represented ~10 and >30-fold excess above the HCV replicon EC50 value, respectively. Mean reductions of HCV RNA from baseline to day seven with TMC435 alone and in triple therapy were 2.63 and 3.47 log10 ...

Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic

... that IDX375 targets the palm non-nucleoside pocket of HCV polymerase. IDX375 has exhibited single nanomolar in vitro potency against HCV genotype 1b replicon (EC50 = 2 nM) and against HCV genotype 1a and 1b polymerases. Additionally, cellular cytotoxicity testing in Huh-7 cells demonstrated that IDX375 is ...

Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results

... preclinical data from its HCV protease inhibitor program, with internally discovered compounds exhibiting potency in the HCV replicon system and good pharmacokinetic profiles in several animal species. "We have made significant progress in the last six months in ...
Replicon in Biological News

Evolutionary origin of bacterial chromosomes revealed

... I and III, Agrobacteria gene movements have produced second chromosomes derived from plasmids, while in the biovar II strain K84 the plasmid-based replicon has yet to reach second chromosome status." Derek Wood, associate professor at Seattle Pacific University, remarked: "The findings in this work ...

Hepatitis C complicated by morphine withdrawal

... withdrawal enhances hepatitis C virus (HCV) replicon expression, appears in the November issue of The ... measure HCV replication, they used a virus-like replicon that mimics the events that occur in liver cells ... RNA and proteins that HCV uses. Although the replicon does not produce the infectious virus, the ...

Cyclosporine inhibits hepatitis C virus in vitro

... on hepatitis C in vitro. For the in vitro study, the researchers, led by Roberto J. Firpi, M.D. of the University of Florida, treated the HCV replicon line, GSB1, with varying doses of Cyclosporine for 48 hours and examined the results. They found that Cyclosporine reduced HCV replication by 20 ...

Texas scientists discover how a hepatitis C protein promotes liver cancer

... hepatitis C genetic material that is able to reproduce itself in cultured cells and also able to produce proteins made by hepatitis C viruses. "The replicon experiments enabled us to identify a protein known as NS5B that attaches to the retinoblastoma protein, a critical tumor suppressor, and accelerates ...

A comprehensive response to HIV could prevent 10 million AIDS deaths in Africa by 2020

... the researchers inserted the gene for the HER2/neu protein in place of the deleted viral genes and then packaged the virus vector into virus-like replicon particles, referred to as “VRP-neu.?When these non-propagating particles are injected into an animal, the vector directs the animal’s cells to make ...

Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer

... the researchers inserted the gene for the HER2/neu protein in place of the deleted viral genes and then packaged the virus vector into virus-like replicon particles, referred to as “VRP-neu.?When these non-propagating particles are injected into an animal, the vector directs the animal’s cells to make ...

More>>

Replicon in Biological Technology

GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology

... efficacy using the industry gold standard replicon assay without significantly increased toxicity as ... in vitro in the HCV genotype 1b subgenomic replicon assay (BM4-5 cells) as compared to IFN alpha 2. ... alpha 2. - Viral clearance of HCV genotype 1b replicon subgenome was obtained in BM4-5 cells after ...

InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting

... assays. One assay modeled HCV replication (14-day replicon clearance assay) and the other assay modeled ... in significantly enhanced clearance of the HCV replicon and reduced or suppressed the emergence of ... of the NS5B Inhibitors R1626 or R7128 Enhances replicon Clearance and Reduces the Emergence of Drug ...

InterMune Reports Third Quarter 2008 Financial Results and Business Highlights

... moiety of polymerase inhibitor R7128 (Roche/Pharmasset) in a 14-day replicon clearance assay and in a 3-week colony formation assay resulted in clearance of the HCV replicon and reduced or suppressed the emergence of drug-resistant viral ...

InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting

... follows: Combination of the NS3/4A Protease Inhibitor ITMN-191 with the Allosteric NS5B Polymerase Inhibitor ITMN-8020 Enhances replicon Clearance and Reduces the Emergence of Drug Resistant Variants . Discovery of Potent, Bioavailable HCV NS3/4A Inhibitors that Display ...

Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan

... as a treatment of chronic hepatitis C. Nitazoxanide is a potent inhibitor of hepatitis C virus (HCV) replication in HCV genotype 1-derived replicon cell lines, and in vitro studies have shown that it does not induce mutations in the virus that confer resistance. In phase II clinical trials, the ...

Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C

... as a treatment of chronic hepatitis C. Nitazoxanide is a potent inhibitor of hepatitis C virus (HCV) replication in HCV genotype 1-derived replicon cell lines, and in vitro studies have shown that it does not induce mutations in the virus that confer resistance. In phase II clinical trials, the ...

Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights

... interferon-alpha and non-antagonistic with ribavirin in cell-based assays. ANA598 was also shown to retain full activity against a number of replicon mutations known to confer resistance to other anti-HCV agents currently in clinical development, including protease inhibitors and nucleoside ...

XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals

... production. NS5A is distinct from the protease and polymerase. The Program's lead compounds are highly potent inhibitors of viral replication in the replicon assay, which is known to have good correlation with clinical efficacy and is currently the leading method for preclinical testing of inhibitors of ...

Your Data: Silencing Hepatitis C Virus Replication With In Vitro Transcribed siRNAs

... multiple siRNAs targeting various regions of the HCV subgenomic replicon sequence. These siRNAs were transfected into an Huh-7 cell line that stably expressed the HCV RNA replicon and screened for their gene silencing activities by real-time ...
Replicon in Biological Dictionary

Replicon

... A replicon is a DNA molecule or RNA molecule, or a region ... from a single origin of replication. A replicon in genetics is a region of DNA or RNA, that replicates from a single ... replicon is a software company providing timesheet and ...

More>>

Other Contents
(Date:7/13/2014)... treatment and variations in the quality of care are ... patients still varies widely between regions within Europe, according ... adults to date, published in The Lancet Oncology ... for most cancers of the blood has increased over ... of new targeted drugs in the early 2000s such ...
(Date:7/13/2014)... type-1 diabetes could improve patient care worldwide and ... the device,s inventors at the Stanford University School ... be published online July 13 in Nature ... type-1 diabetes outside hospital settings. The handheld microchips ... mellitus, which are both characterized by high blood-sugar ...
(Date:7/13/2014)... irrigation systems are mainly utilized for agriculture in order ... maintain soil quality. The application of micro irrigation systems ... generator for manufacturers in future. The trend of utilizing ... to the adoption of micro irrigation techniques for agriculture, ... for micro irrigation systems, as they reduce the overall ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on the ... rendering; Layout and Animation; Image Reconstruction]: Global Advancements, ... analyzes and studies the major market drivers, restraints, ... Europe, Middle East and Africa, Asia-Pacific and Latin ... of the 3D imaging market, providing an in-depth ...
(Date:7/13/2014)... The federal court overseeing thousands of ... against Johnson & Johnson’s Ethicon, Inc. is preparing to ... to get underway next month. According to an Amended ... Southern District of West Virginia on July 9, 2014, ... 2014 at 3:00 p.m. July selection is slated to ...
Breaking Medicine News(10 mins):Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4
(Date:7/11/2014)... kidney injury related to the use of hydroxyethyl starch ... molecules, according to a report in Anesthesia & ... Society (IARS). , The "total mass of HES molecules" ... renal proximal tubule cells (PTCs), concludes the laboratory study ... Wrzburg, Austria. Other factorssuch as differences in the ...
(Date:7/11/2014)... 2014 Research and Markets has ... Market - Industry Analysis Size Share Growth Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 The ... a need for high level security in both private ... such as username and passwords, tokens etc. are vulnerable ...
(Date:7/10/2014)... YORK , June 27, 2014  Pomerantz ... Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) ... filed in United States District Court, Middle District ... is on behalf of a class consisting of ... acquired Provectus securities between December 17, 2013 and ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
Other TagsOther Tags